Changho Choi, Ph.D., received his Bachelor of Science degree in 1987 from Korea University, South Korea. He then earned a Ph.D. from the University of Waterloo, Canada, where he used nuclear magnetic resonance for studying quantum tunneling of protons at low temperatures. Following several years of research in in-vivo MR spectroscopy (MRS), he joined the Advanced Imaging Research Center at UT Southwestern Medical Center in 2007.

Dr. Choi’s research has been focused on both technical and clinical developments of MR spectroscopy in brain tumors and neuropsychiatric disorders. MRS methodology development has been carried out to provide meaningful measurements of clinically-important hard-to-detect brain metabolites, including 2-hydroxyglutarate (2HG), citrate, GABA, glycine, glutamate and glutamine, etc.  Specifically, 2HG, which is a direct consequence of IDH mutation in gliomas, appears to be an unprecedented imaging biomarker in brain tumors.

Research is going on to accomplish a fast, high-precision 2HG imaging modality, in parallel with translation of previously-developed methods into clinics. The clinical utility of 2HG, glycine and citrate in brain tumors is investigated in collaboration with neuro-oncologists. Also, several MRS studies are conducted to evaluate the alterations in metabolic profiles in neurological diseases, including schizophrenia, asthma and autism, in collaboration with psychiatrists.


Korea University (1987), Physics
Graduate School
Korea University (1989), Physics
Graduate School
University of Waterloo (1996), Physics

Research Interest

  • Applications of MRS in cancer and neuropsychiatric diseases
  • In vivo 1H and 13C MR spectroscopy
  • Quantum mechanical simulations of spin dynamics
  • RF pulse and MRS sequence design


Featured Publications LegendFeatured Publications

Prospective longitudinal analysis of 2-hydroxyglutarate MR spectroscopy identifies broad clinical utility for the management of IDH-mutant glioma patients
Choi C, Raisanen JM, Ganji SK, Zhang S, McNeil SS, An Z, Madan A, Hatanpaa KJ, Vemireddy V, Sheppard CA, Oliver D, Hulsey KM, Tiwari V, Mashimo T, Battiste J, Barnett S, Madden CJ, Patel TV, Pan E, Malloy CR, Mickey BE, Bachoo RM, Maher EM Journal of Clinical Oncology (Published online) 2016
Non-invasive assessment of Isocitrate dehydrogenase (IDH) mutational status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting
Tietze A, Choi C, Mickey B, Maher EA, Ulhøi BP, Sangill R, Ramshad-Lassen Y, Lukacova S, Østergaard L, von Oettingen G Journal of Neuro-surgery (Accepted) 2016
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB Neuro-oncology 2015 Dec
In vivo (1) H MRSI of glycine in brain tumors at 3T.
Ganji SK, Maher EA, Choi C Magn Reson Med 2015 Feb
(1) H MRS characterization of neurochemical profiles in orthotopic mouse models of human brain tumors.
Hulsey KM, Mashimo T, Banerjee A, Soesbe TC, Spence JS, Vemireddy V, Maher EA, Bachoo RM, Choi C NMR Biomed 2014 Nov
Measurement of regional variation of GABA in the human brain by optimized point-resolved spectroscopy at 7?T in vivo.
Ganji SK, An Z, Banerjee A, Madan A, Hulsey KM, Choi C NMR Biomed 2014 Aug
Proton T2 measurement and quantification of lactate in brain tumors by MRS at 3 Tesla in vivo.
Madan A, Ganji SK, An Z, Choe KS, Pinho MC, Bachoo RM, Maher EM, Choi C Magn Reson Med 2014 Jul